Abstract
Introduction

Metastatic prostate cancer is an incurable disease often treated initially using one of many hormone therapies. Patients inevitably develop resistance to these therapies [1], and only 33% survive more than 5 years after diagnosis of metastatic disease [2]. In efforts to develop more effective therapeutic approaches, researchers have historically studied the prostate cancer cells themselves. However, in recent years, they have begun to study the cancer cells' interactions with their associated microenvironment, including stromal cells such as fibroblasts
.
Prostate fibroblasts have been shown to promote prostate cancer progression in various ways: for example, by secreting factors that enhance tumour growth [5] [6] [7] [8] [9] and by inducing the migration [10] and invasion of prostate cancer cells through Matrigel [11] and collagen [12] . Fibroblasts reside in the collagen-rich connective tissue of the prostate [13, 14] , a compartment that prostate cancer cells enter after invading through the basement membrane en route to the tumour vasculature [15] . It (EC 3.1.27) [16] [17] [18] , a pro-angiogenic polypeptide that stimulates endothelial cell invasion [19] 
Western blotting
PrSC and PCAF whole-cell lysates were prepared using lysis buffer (20- (Fig. 3A) . Fig. 3B ). To verify that the source of angiogenin was the prostates rather than the sera within the prostates, we also performed cytokine antibody array 6 analysis of sera from prostate cancer patients. Angiogenin was not detected in these samples (Fig. 3B) , suggesting that the source of angiogenin present in the prostatic fluid samples was the prostates themselves.
Cytokine profiles of CM, prostatic fluids and sera
We next wanted to identify candidate protein(s) in prostate cancer CM that may be involved in the stimulation of PrSC and PCAF invasion. To this end, we performed cytokine antibody array 6 analysis of PC-3-, LNCaP-and DU145-CM. We found that all three CM contained the pro-angiogenic polypeptide angiogenin
To determine whether these findings are clinically relevant, we performed cytokine antibody array 6 analysis of prostatic fluid samples obtained at the time of surgery for prostate cancer. Angiogenin was detected in all of the samples tested, including those from 22 patients with minimal prostate cancer and 18 patients with extensive prostate cancer (partial data shown in
PrSC and PCAF invasion through collagen I in response to angiogenin-blocked PC-3-CM
Angiogenin has been shown to stimulate the invasion of endothelial cells [19] . Based on this finding and our own data demonstrating that various prostate cancer cell lines secrete angiogenin (Fig. 3A) , we wanted to determine whether angiogenin could stimulate the invasion of prostate fibroblasts. We therefore blocked angiogenin in PC-3-CM using a polyclonal goat anti-angiogenin antibody and then tested the CM in collagen I invasion assays. We found that blocking angiogenin completely and significantly abrogated PC-3-induced PrSC and PCAF invasion, while blocking an irrelevant protein, hnRNP A1, did not (Fig. 4) (Fig. 5A ). An angiogenin ELISA on the CM confirmed that the angiogenin siRNA resulted in a decrease in angiogenin protein (Fig. 5B) . Together, these data provide additional evidence that PC-3-derived angiogenin stimulates collagen I invasion of both normal prostate fibroblasts and PCAFs.
PrSC and PCAF invasion through collagen I in response to angiogenin
To determine whether angiogenin is sufficient for stimulating PrSC and PCAF invasion through collagen I, we tested angiogenin alone for its ability to produce this effect. Because the angiogenin concentration was determined by ELISA to be 1.55 Ϯ 0.04 ng/ml in CM from negative control siRNA-treated PC-3 (Fig. 5B) ( Fig. 5A) , we tested similar angiogenin concentrations (1, 2 and 5 ng/ml) in collagen I invasion assays. Angiogenin stimulated PrSC invasion only minimally but PCAF invasion significantly, especially at higher concentrations (Fig. 6) . These results suggest that angiogenin may be sufficient to stimulate the invasion of PCAFs, but not normal prostate fibroblasts, through collagen I. 
Discussion
199
assess fibroblast migration and invasion in prostate cancer, although these phenomena have been studied for other cancers. For example, some studies have described examples in which bladder cancer stroma invaded the prostate in cancer patients [22, 23] , and another study showed that fibroblasts invaded mammary and hepatocellular tumours in mice [24] .
Both PrSCs and PCAFs responded to PC-3-, LNCaP-and DU145-CM; however, they migrated and invaded to a different extent in response to each CM (Fig. 2) [4, 25] as well as their expression of various stromal markers [13] and growth factors [25] Angiogenin has been shown to stimulate endothelial cell invasion by binding to smooth muscle ␣-actin on the cell surface [26] to form a complex that then dissociates from the cell membrane [26, 27] and activates tissue plasminogen activator (tPA) [19, 26] . tPA catalyses the conversion of plasminogen into plasmin, which in turn can activate matrix metalloproteinases (MMPs) [28] [30] , a monoclonal anti-angiogenin antibody [31, 32] , and other angiogenin antagonists [33] . In another study, both in vitro and in vivo prostate cancer growth were inhibited by knocking down angiogenin expression in PC-3 cells [34] . Furthermore, angiogenin expression in tissue [16] and plasma [35] 
